Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PerkinElmer Introduces Novel Research Tools at SLAS 2014

Published: Monday, January 27, 2014
Last Updated: Monday, January 27, 2014
Bookmark and Share
PerkinElmer Inc. introduced several novel products at SLAS2014, including the Opera® Phenix™ high content screening system, JANUS® chemagic nucleic acid workstation.

"We are excited to participate in this important event for our industry as we continue to listen and learn from our customers, helping advance transformative science and build upon a legacy of innovation in automation, detection and screening solutions,” said Jim Corbett, President, Life Sciences and Technology, PerkinElmer. "Advances in phenotyping complex cellular models and innovations in genomics, particularly rapid, high throughput nucleic acid extraction, offer new tools to accelerate our understanding of cancer and other life threatening diseases, as well as enable customers to bring better, more effective therapeutics to market." 

PerkinElmer products on display at SLAS 2014 include:

• Opera® Phenix, a next generation confocal high content screening system, is designed to reliably discriminate phenotypes of complex cellular models, such as primary cells and 3D microtissue, which are more indicative of human biology. Accurate, reliable characterization of cellular processes can further scientists’ understanding of cancer cell morphology and therefore the development of targeted cancer treatments. The system’s patented Synchony Optics™ control excitation to eliminate unwanted crosstalk in the sample, resulting in better sensitivity but without compromising speed. Data generated using the Phenix® imaging system can be processed seamlessly with PerkinElmer’s Harmony® High Content Imaging and Analysis Software, an intuitive workflow-based interface optimized for processing large volumes of data. 

• The JANUS® chemagic automated nucleic acid workstation offers high throughput DNA and RNA extraction with four times the yield and twice the throughput of alternate technologies. A fully integrated system, this workstation combines best-in-class magnetic bead nucleic acid isolation technology with a fully-supported automated liquid handler to rapidly accelerate the extraction process. Standardized protocols are designed for volume ranges of 10µl up to 4mL, resulting in reproducible, high throughput extraction from a variety of blood input sample types for downstream processing including PCR/qPCR, Sanger or next gen sequencing, microarrays and genotyping.

• Dedicated AlphaLISA® immunoassay kits for isotyping human and mouse antibodies provide high specificity and low cross-reactivity between isotypes, without compromising sensitivity or throughput. 

• AlphaLISA kits and toolbox reagents for metabolic disease research with biomarkers including Glucagon, Insulin, Leptin, C-peptide, and FGF21

• AlphaLISA kits for cell-based epigenetic ubiquitination which enable scientists to fully validate the mechanism of action of drugs thought to act on methyltransferase (eg. EZH2) or demethylase (eg. JMJD2A, JMJD3) enzymes in cell-based assays by testing their capacity to modulate H2a ubiquitination. These kits allow considerable time-savings over Enzyme-linked immunosorbent assay (ELISA) technology, commonly used to perform immunoassays. 

The above products are for research use only and not for use in diagnostic procedures.

• SciStream™, new software enabling the easy import of plate-based and other forms of instrument data into the TIBCO Spotfire® Analytics and Visualization Platform.  SciStream unlocks the power of TIBCO Spotfire software for users of plate readers, high content imaging systems and other instruments, enabling researchers to easily and dynamically visualize their experimental data, metadata and plate layouts with unprecedented speed and interactivity.  Faster visualization and analysis in TIBCO Spotfire software leads to scientific insights much more quickly than using traditional tools for assay development as well as large screening campaigns.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PerkinElmer, Sofie Biosciences Announce Benchtop PET Imaging Partnership
Preclinical PET imaging instruments in benchtop format help support high performance disease research, drug discovery and clinical translational applications.
Tuesday, June 10, 2014
Good Start Genetics, PerkinElmer Collaboration Expands Access to Genetic Carrier Screening Tests
Strategic agreement will broaden access to GoodStart Select™ tests to include obstetrics and gynecology and maternal fetal medicine physicians.
Monday, March 17, 2014
PerkinElmer to Host Revolutionaries for Global Health Summit
Company to assemble thought leaders to share pioneering personalized health research and innovations.
Wednesday, May 01, 2013
PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates
The company announced the launch of four new cellular assay kits to help identify and characterize possible drug candidates targeting epigenetic enzymes related to key disease states.
Tuesday, February 07, 2012
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!